Vol 5, No 3 (2020)
Letter to the Editor
Published online: 2020-06-15
Interferon lambda with remdesivir as a potential treatment option in COVID-19
Disaster Emerg Med J 2020;5(3):174.
Abstract
Not available
Keywords: remdesivirinterferon lambdaCOVID-19SARS-CoV-2treatment
References
- Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 [Epub ahead of print].
- Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020; 40(1): 68–76.
- Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020; 295(20): 6785–6797.
- Hemann EA, Schwerk J, Savan R. IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol. 2017; 18(10): 1061–1062.
- Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010; 84(11): 5670–5677.